NCT04786964
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04786964
Title Study of Pemetrexed+Platinum Chemotherapy With or Without Cosibelimab (CK-301) in First Line Metastatic Non-squamous Non-Small Cell Lung Cancer (CONTERNO)
Acronym CONTERNO
Recruitment Terminated
Gender both
Phase Phase III
Variant Requirements No
Sponsors Checkpoint Therapeutics, Inc.
Indications
Therapies
Age Groups: adult | senior
Covered Countries NZL | BRA

Facility Status City State Zip Country Details
Research Site Vitória Brazil Details
Research Site Tbilisi Georgia Details
Research Site Kota Bharu Malaysia Details
Research Site Wellington New Zealand Details
Research Site Lima Peru Details
Research Site Arkhangelsk Russia Details
Research Site Chelyabinsk Russia Details
Research Site Kaliningrad Russia Details
Research Site Kazan' Russia Details
Research Site Kursk Russia Details
Research Site Kuzmolovskiy Russia Details
Research Site Moscow Russia Details
Research Site Nizhny Novgorod Russia Details
Research Site Novosibirsk Russia Details
Research Site Omsk Russia Details
Research Site Saint Petersburg Russia Details
Research Site Samara Russia Details
Research Site Sochi Russia Details
Research Site Tomsk Russia Details
Research Site Volgograd Russia Details
Research Site Pretoria South Africa Details
Research Site Chiang Mai Thailand Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field